Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs
- PMID: 8035322
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs
Abstract
Selective inhibition of phosphodiesterase (PDE) isozymes has been shown to inhibit inflammatory cell function and relax airway smooth muscle and, thus, may be useful in the therapy of asthma. In guinea pigs sensitized to ovalbumin (OA), the effects of three PDE inhibitors were compared: siguazodan (PDE III selective, IC50 = 0.7 microM), rolipram (PDE IV selective, IC50 = 0.8 microM) and zardaverine (dual PDE III/IV, IC50S = 2.5 microM and 1.1 microM, respectively) against histamine-, leukotriene (LT) D4- and OA-induced bronchospasm in vitro and in vivo. Rolipram or zardaverine (0.1-10 microM), but not siguazodan, inhibited OA-induced contraction of the isolated trachea in a concentration-dependent manner. Rolipram or siguazodan alone (10 microM) were ineffective against histamine- or LTD4-induced contractions. Zardaverine alone (10 microM) or the combination of rolipram and siguazodan (10 microM each) markedly antagonized the contractions elicited by both spasmogens. In anesthesized, ventilated guinea pigs, the i.v. ID50S against OA-induced bronchospasm were: rolipram = 0.2 mg/kg, siguazodan > 10 mg/kg and zardaverine = 2.4 mg/kg. When administered at doses up to 7.5 mg/kg, i.v., rolipram or siguazodan were markedly less effective (i.e., < or = 50% inhibition) than zardaverine (ID50S = 2.4 and 1.7 mg/kg, respectively) at blocking exogenous histamine- or LTD4-induced bronchospasm. However, when administered in combination with siguazodan (5.4 mg/kg, i.v.), rolipram (0.4-5.4 mg/kg) abolished histamine- and LTD4-induced bronchoconstriction. In conscious guinea pigs, zardaverine (5 mg/kg, intragastrically (i.g.) or the combination of rolipram and siguazodan (5 mg/kg each) were substantially more effective than rolipram or siguazodan alone at inhibiting aerosol histamine- or LTD4-induced bronchospasm. In the same animals, rolipram or zardaverine (5 mg/kg, i.g.) but not siguazodan (5 mg/kg, i.g.) markedly inhibited aerosol OA-induced bronchoconstriction. The OA-induced pulmonary eosinophil infiltration in these animals was attenuated by all treatments with zardaverine producing the greatest degree of inhibition. These results indicate that 1) PDE IV inhibitors but not PDE III inhibitors are effective at blocking antigen-induced bronchospasm, 2) compounds that selectively inhibit either PDE III or PDE IV are poor inhibitors of bronchoconstriction elicited by exogenously administered spasmogens, and 3) the combined inhibition of both PDE III and PDE IV isozymes acts in an additive or synergistic manner to inhibit bronchospasm in the guinea pig.
Similar articles
-
Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.J Pharmacol Exp Ther. 1993 Jul;266(1):306-13. J Pharmacol Exp Ther. 1993. PMID: 8392555
-
Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.J Pharmacol Exp Ther. 1993 Feb;264(2):609-15. J Pharmacol Exp Ther. 1993. PMID: 8437112
-
Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.J Pharmacol Exp Ther. 1995 Aug;274(2):678-87. J Pharmacol Exp Ther. 1995. PMID: 7636728
-
Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.Agents Actions Suppl. 1991;34:379-402. Agents Actions Suppl. 1991. PMID: 1665311 Review.
-
PDE isoenzymes as targets for anti-asthma drugs.Eur Respir J. 1995 Jul;8(7):1179-83. doi: 10.1183/09031936.95.08071179. Eur Respir J. 1995. PMID: 7589403 Review.
Cited by
-
Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.Br J Pharmacol. 2000 May;130(2):457-63. doi: 10.1038/sj.bjp.0703308. Br J Pharmacol. 2000. PMID: 10807686 Free PMC article.
-
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.Inflammation. 2000 Aug;24(4):317-29. doi: 10.1023/a:1007092830169. Inflammation. 2000. PMID: 10850854
-
The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.Br J Pharmacol. 1999 Feb;126(4):979-88. doi: 10.1038/sj.bjp.0702387. Br J Pharmacol. 1999. PMID: 10193778 Free PMC article.
-
Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility.Br J Pharmacol. 2016 Aug;173(15):2335-51. doi: 10.1111/bph.13512. Epub 2016 Jul 7. Br J Pharmacol. 2016. PMID: 27174172 Free PMC article.
-
Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism.Br J Pharmacol. 2009 Jan;156(1):105-15. doi: 10.1111/j.1476-5381.2008.00012.x. Epub 2008 Dec 6. Br J Pharmacol. 2009. PMID: 19068077 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources